Daraxonrasib clinical trials
Also written RMC-6236.
How each study uses daraxonrasib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the daraxonrasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Aug 2026 · RASONQUE · NDA 220910 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2026 (4); 3 more planned to start later
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 4
Revolution Medicines, Inc. (10) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · National Health Research Institutes, Taiwan (1) · Dana-Farber Cancer Institute (1) · Children's Oncology Group (1)
Often tested with
Tested in the same studies.
Zoldonrasib (3) · Gemcitabine (2) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Elironrasib (2) · Cetuximab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test daraxonrasib.
- May 2027Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPhase 1/2 · Revolution Medicines, Inc.
- Jun 2027Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCPhase 1/2 · Revolution Medicines, Inc.
Studies
Open first, then newest update. How each study uses daraxonrasib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07491445Written as daraxonrasib
- Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerNot yet recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07793253Alone in KRAS-mutant biliary tract cancerWritten as Daraxonrasib
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)RecruitingPhase 3Revolution Medicines, Inc.NCT06881784Against docetaxel in RAS-mutant lung cancerWritten as daraxonrasib
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07805954With zoldonrasib, against chemotherapy, first line in G12D pancreatic cancerWritten as daraxonrasib
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT07397338With ivonescimab, with or without chemotherapyWritten as Daraxonrasib
- Daraxonrasib in Asian RAS-mutant Biliary Tract CancerNot yet recruitingPhase 2National Health Research Institutes, TaiwanNCT07908550Alone in Asian patients with RAS-mutant biliary tract cancerWritten as Daraxonrasib
- Daraxonrasib in Resectable PDACNot yet recruitingPhase 1Dana-Farber Cancer InstituteNCT07898813Before and after surgery for resectable pancreatic cancerWritten as Daraxonrasib
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)RecruitingPhase 3Revolution Medicines, Inc.NCT07252232Against observation after surgery for pancreatic cancerWritten as daraxonrasib
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingPhase 1/2Revolution Medicines, Inc.NCT06162221With pembrolizumab, chemotherapy or other RAS(ON) inhibitors in lung cancerWritten as RMC-6236
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06445062With chemotherapy, bevacizumab or cetuximab in digestive cancersWritten as RMC-6236
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06128551Alone and with elironrasib in KRAS G12C tumoursWritten as Daraxonrasib
- Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS MutationsNot yet recruitingPhase 1/2Children's Oncology GroupNCT07819838Alone in children with RAS-mutant solid tumoursWritten as Daraxonrasib
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRecruitingPhase 1/2Revolution Medicines, Inc.NCT05379985Alone in RAS-mutant solid tumours, first in peopleWritten as RMC-6236
- Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Active, not recruitingPhase 3Revolution Medicines, Inc.NCT06625320On the US labelAgainst chemotherapy in previously treated pancreatic cancerWritten as RMC-6236
Behind its US label · 1 — the studies the FDA label of RASONQUE describes
From the Clinical Studies section of RASONQUE (2026-08), as openFDA has it. A study the site does not hold is left out.
Given beside what is tested · 7 — daraxonrasib is usual care or a partner of the new treatment
- A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)RecruitingPhase 2Bristol-Myers SquibbNCT07492680Given with navlimetostat in some cohortsWritten as Daraxonrasib
- First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic CancerRecruitingPhase 1ParVation Therapeutics, Inc.NCT07756281Given with SNV1521, the drug being dosedWritten as daraxonrasib
- A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07895498Taken in every arm; the study treats the rash it causes
- Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsRecruitingPhase 1/2Tango Therapeutics, Inc.NCT06922591Given with TNG462, the drug being dosedWritten as RMC-6236
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsRecruitingPhase 1Revolution Medicines, Inc.NCT07349537Given with RMC-5127 in one armWritten as daraxonrasib
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsRecruitingPhase 1Revolution Medicines, Inc.NCT06040541Given with zoldonrasib in its combination armWritten as RMC-6236
- A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)Active, not recruitingPhase 1AmgenNCT06360354Given with anvumetostat in one pancreatic cancer subprotocolWritten as RMC-6236
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered2
- Daraxonrasib in Asian RAS-mutant Biliary Tract CancerNov 2, 2026NCT07908550
- Daraxonrasib in Resectable PDACOct 27, 2026NCT07898813
Codes
What other systems call daraxonrasib · ClinicalTrials.gg INT002100
- MeSH (NLM) C000731071daraxonrasibOne source NLM
- UNII (FDA) B6T47Y2UAPDARAXONRASIBConfirmed FDA, NLM, Wikidata
- Wikidata Q136659312daraxonrasibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C188048DaraxonrasibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731071 | daraxonrasib | One source NLM |
| UNII (FDA) | B6T47Y2UAP | DARAXONRASIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q136659312 | daraxonrasib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C188048 | Daraxonrasib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.